Pharmacologic treatments for covid-19 patients

Methods

Protocol

Protocol amendment:

As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

For treatments that are neither immunomodulators nor antivirals, we provide the updated results up to Feb 28, 2022 including all identified reports through our search strategy up to this date.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Treatment comparisons

Of note, as of March 1, 2022, the COVID-NMA revised its protocol and reduced its scope.
Only comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

Create and download your forest plots with the most up-to-date data here Forest plots

Access the forest plots for the 357 treatment comparisons .

Search studies

Search by Author Registration number

General characteristics of primary studies

Page: 1 / Sorted by: Most recent ↓
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
New
NCT04501978
ACTIV-3/TICO Study Group, Ann Intern Med, 2022
Full text
Commentary
Commentary
Mixed

Ensovibep

Placebo

RCT Patients with confirmed COVID-19 (mild-moderate-severe) admitted to 62 centers in USA, Greece, Uganda, Singapore, UK, Nigeria, Denmark, Switzerland, Poland, and Spain. N=496
Some concerns
Details

Full description

NCT04712357
Arruda EAG, medRxiv, 2021
Full text
Commentary
Commentary
Public/non profit

Tenofovir

Tenofovir+Emtricitabine

Tenofovir

Placebo

Placebo

Tenofovir+Emtricitabine

RCT Outpatients with suspected or confirmed COVID-19 (mild) treated at a single center in Brazil. N=139
Some concerns
Details

Full description

ISRCTN30448031; EudraCT: 2021-005748-31
PANORAMIC
Butler C, SSRN, 2022
Full text
Commentary
Public/non profit

Molnupiravir

Standard care

RCT Outpatients with confirmed COVID-19 (mild-ambulatory) treated by multiple centers in the UK N=25783
High
Details

Full description

ChiCTR2200056817
Zou R, Front Pharm, 2022
Full text
Commentary
Mixed

Molnupiravir

Standard care

RCT Patients with confirmed COVID-19 (mild) isolated and treated by a single center in China N=116
Some concerns
Details

Full description

NCT04583592
CAMELOT
NCT04583592, Unpublished, 2022
Full text
Not reported/unclear

Camostat Mesilate

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by multiple centers in the USA. N=295
Low
Details

Full description

NCT04524663
COPS-2003
NCT04524663, Unpublished, 2022
Full text
Not reported/unclear

Camostat Mesilate

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by one center in the USA. N=49
Some concerns
Details

Full description

NCT04369469
NCT04369469, Unpublished, 2022
Full text
Not reported/unclear

Ravulizumab

Standard care

RCT Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in France, Japan, Spain, UK and the USA. N=202
Some concerns
Details

Full description

NCT04385199
NCT04385199, Unpublished, 2022
Full text
Not reported/unclear

Convalescent plasma

Standard care

RCT Patients with confirmed COVID-19 (severe-critical) admitted to a single center in the USA. N=30
Some concerns
Details

Full description

EudraCT2020-001156-18
PANCOVID
Montejano R, Clin Infect Dis, 2022
Full text
Commentary
Commentary
Mixed

Tenofovir + Emtricitabine + Dexamethasone + Baricitinib

Baricitinib + Dexamethasone

Tenofovir + Emtricitabine + Dexamethasone

Dexamethasone

RCT Patients with confirmed COVID-19 (mild-severe) admitted to or treated by 25 centers in Spain. N=287
Some concerns
Details

Full description

NCT04746183; ISRCTN27106947; EudraCT 2020-001860-2
AGILE CST-2
Khoo SH, medRxiv, 2022
Full text
Commentary
Commentary
Mixed

Molnupiravir

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by 5 centers in the UK N=180
Some concerns
Details

Full description